

Metadata

- Document Type: Drug Information Sheet
- Specialty: Infectious Diseases
- Keywords: Antiviral therapy, remdesivir, COVID-19 treatment
- Date: September 10, 2025

Title

Remdesivir: Antiviral Agent for COVID-19

Abstract

This drug information sheet provides clinicians with details regarding remdesivir, its mechanism, indications, dosing, adverse effects, and monitoring requirements.

Main Content

Class

Antiviral - nucleoside analogue RNA polymerase inhibitor.

Mechanism of Action

Remdesivir inhibits viral RNA-dependent RNA polymerase, reducing replication of SARS-CoV-2.

Indications

- Hospitalized patients with confirmed COVID-19 requiring supplemental oxygen but not on invasive ventilation.

Dosage

- Loading dose: 200 mg IV on Day 1
- Maintenance dose: 100 mg IV daily for 4 to 9 days depending on clinical response

Adverse Effects

- Nausea, transaminase elevations
- Rare: hypersensitivity reactions, renal dysfunction

Monitoring

- Baseline liver and renal function tests, with periodic monitoring during treatment

Contraindications

- Severe renal impairment (eGFR <30 mL/min)
- Known hypersensitivity to remdesivir

References

1. Silva R, Gomez F. Antivirals in COVID-19 management: Focus on remdesivir. *Infect Dis Clin J* 2024;19(2):75-83.
2. Ahmad A, Patel S. Safety monitoring of remdesivir in hospitalized patients. *Int J Infect Ther* 2023;11(1):42-47.